Some Issues of Sample Size Calculation for Time-to-Event Endpoints Using the Freedman and Schoenfeld Formulas
Authors:
- 23 January 2015
- journal article
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 25 (6) , 1285-1311
Abstract
This article deals with seven special issues related to the assumptions, applicability, and practical use of formulas for calculating power or sample size, respectively, for comparative clinical trials with time-to-event endpoints, with particular focus on the well-known Freedman and Schoenfeld methods. All problems addressed are illustrated by numerical examples, and recommendations are given on how to deal with them in the planning of clinical trials.Keywords
This publication has 34 references indexed in Scilit:
- Improved Endpoints for Cancer Immunotherapy TrialsJNCI: Journal of the National Cancer Institute, 2010
- Adaptive trial design: A general methodology for censored time to event dataContemporary Clinical Trials, 2009
- Evaluation of sample size and power for multi-arm survival trials allowing for non-uniform accrual, non-proportional hazards, loss to follow-up and cross-overStatistics in Medicine, 2006
- Power estimation for rank tests using censored data: Conditional and unconditionalControlled Clinical Trials, 1991
- Determining the duration of comparative clinical trials while allowing for cureJournal of Chronic Diseases, 1985
- Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observationJournal of Chronic Diseases, 1981
- Breast cancer: The error of the exponentialEuropean Journal of Cancer (1965), 1978
- Planning the size and duration of a clinical trial studying the time to some critical eventJournal of Chronic Diseases, 1974
- Planning the duration of long-term survival time studies designed for accrual by cohortsJournal of Chronic Diseases, 1971
- Survival Curve for Cancer Patients Following TreatmentJournal of the American Statistical Association, 1952